

# Xenofon Baraliakos

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6929550/xenofon-baraliakos-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

319  
papers

14,956  
citations

59  
h-index

118  
g-index

441  
ext. papers

18,598  
ext. citations

3.9  
avg, IF

6.39  
L-index

#	Paper	IF	Citations
319	Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series.. <i>Clinical Case Reports (discontinued)</i> , <b>2022</b> , 10, e05205	0.7	2
318	Striking sex differences in magnetic resonance imaging findings in the sacroiliac joints in the population.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 29	5.7	0
317	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.. <i>Acta Dermato-Venereologica</i> , <b>2022</b> ,	2.2	4
316	Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes.. <i>Rheumatology and Therapy</i> , <b>2022</b> , 1	4.4	0
315	Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis.. <i>British Journal of Dermatology</i> , <b>2022</b> ,	4	
314	Effects of patient and disease characteristics on global functioning in patients with axial spondyloarthritis in routine care.. <i>Seminars in Arthritis and Rheumatism</i> , <b>2022</b> , 55, 152006	5.3	
313	Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewijck <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,	2.4	1
312	Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis. <i>Cells</i> , <b>2022</b> , 11, 1609	7.9	0
311	What is peripheral spondyloarthritis? Identifying proportion, phenotype and burden in post hoc analysis of the ASAS-PerSpA study.. <i>Seminars in Arthritis and Rheumatism</i> , <b>2022</b> , 55, 152012	5.3	1
310	Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 111	5.7	0
309	Radionuklidtherapie entzündlicher Gelenkerkrankungen <b>2022</b> , 45, 106-109		
308	Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 582-590	2.4	31
307	Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: Results from a Phase 3b trial. <i>Rheumatology</i> , <b>2021</b> ,	3.9	1
306	Value of imaging to guide interventional procedures in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	1
305	Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 779975	4.9	0
304	Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years. <i>Journal of Rheumatology</i> , <b>2021</b> ,	4.1	3
303	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 17597201211057075	3.8	1

302	Inequality of access to advanced therapies for patients with inflammatory arthritis: a postcode lottery?. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkab081	1.1	0
301	Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	1
300	Anti-CD74 IgA autoantibodies in radiographic axial spondyloarthritis: a longitudinal Swedish study. <i>Rheumatology</i> , <b>2021</b> , 60, 4085-4093	3.9	1
299	Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1251-1258	4.1	3
298	Response to: 'Correspondence on 'MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group" by Jibri. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	
297	Root Joint Involvement in Spondyloarthritis: A Post-hoc Analysis from the International ASAS-PerSpA Study. <i>Rheumatology</i> , <b>2021</b> ,	3.9	1
296	SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e481-e488	14.2	8
295	Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	25
294	Response to: 'Correspondence on 'Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?' by Su. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	1
293	Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe. <i>Rheumatology</i> , <b>2021</b> , 60, 113-124	3.9	2
292	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status?. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 856-860	4.7	17
291	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 71-87	2.4	50
290	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 65-70	2.4	2
289	Which Magnetic Resonance Imaging Lesions in the Sacroiliac Joints Are Most Relevant for Diagnosing Axial Spondyloarthritis? A Prospective Study Comparing Rheumatologists' Evaluations With Radiologists' Findings. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 800-805	9.5	7
288	Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 273-288	4.4	7
287	Dose tapering of biologic agents in patients with rheumatoid arthritis-results from a cohort study in Germany. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 887-893	3.9	0
286	New developments in ankylosing spondylitis-status in 2021.. <i>Rheumatology</i> , <b>2021</b> , 60, vi29-vi37	3.9	0
285	Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211041854	3.8	2

284	Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component. <i>Current Rheumatology Reports</i> , <b>2021</b> , 23, 6	4.9	10
283	Radiographic sacroiliitis progression in axial spondyloarthritis: central reading of 5 year follow-up data from the Assessment of SpondyloArthritis international Society cohort. <i>Rheumatology</i> , <b>2021</b> , 60, 2478-2480	3.9	1
282	Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. <i>Rheumatology</i> , <b>2021</b> , 60, 4778-4789	3.9	13
281	A Comprehensive Assessment of Hip Damage in Ankylosing Spondylitis, Especially Early Features. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 668969	8.4	1
280	Engagement process for patients with spondyloarthritis: PANLAR early SpA clinics project - centers of excellence. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 4759-4766	3.9	0
279	Treat-to-target in axial spondyloarthritis - what about physical function and activity?. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 565-576	8.1	7
278	The ASAS-OMERACT core domain set for axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> ,	5.3	6
277	Impact of filgotinib on sacroiliac joint MRI structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial). <i>Rheumatology</i> , <b>2021</b> ,	3.9	2
276	Message from the new EULAR President and Steering Group. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1266-1267	2.4	
275	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. <i>Lancet Rheumatology</i> , <b>2021</b> , 3, e715-e723	14.2	14
274	Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.. <i>BMC Musculoskeletal Disorders</i> , <b>2021</b> , 22, 1037	2.8	2
273	Valeur des stratégies de référence pour le diagnostic de la spondyloarthrite axiale chez les patients ayant une Lombalgie chronique suspecte. <i>Revue Du Rhumatisme (Edition Française)</i> , <b>2021</b> , 88, A152-A153 <sup>0.1</sup>		
272	Facet joint ankylosis in r-axSpA: detection and 2-year progression on whole spine low-dose CT and comparison with syndesmophyte progression. <i>Rheumatology</i> , <b>2020</b> , 59, 3776-3783	3.9	6
271	Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 920-928	2.4	26
270	Response to: 'Frequency of MRI changes suggestive of axial spondyloarthritis in the axial in a large population-based cohort of individuals aged . <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	
269	Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 778-786	2.4	35
268	Early recognition of patients with axial spondyloarthritis-evaluation of referral strategies in primary care. <i>Rheumatology</i> , <b>2020</b> , 59, 3845-3852	3.9	6
267	Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 935-942	2.4	4

266	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 700-712	2.4	238
265	Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 581-599	4.4	6
264	Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2020</b> , 12, 1759720X20906040	2.8	21
263	Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort. <i>PLoS ONE</i> , <b>2020</b> , 15, e0230268	3.7	2
262	Diagnostic capability of contrast-enhanced pelvic girdle magnetic resonance imaging in polymyalgia rheumatica. <i>Rheumatology</i> , <b>2020</b> , 59, 2864-2871	3.9	4
261	Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS). <i>Clinical Drug Investigation</i> , <b>2020</b> , 40, 269-278	3.2	16
260	La progression structurale dans la spondyloarthrite axiale. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2020</b> , 87, 181-186	0.1	
259	Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 294-299	3.5	16
258	Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 595-604	2.4	46
257	OP0086 THE DEGREE OF BONE MARROW EDEMA AS DETECTED BY MAGNETIC RESONANCE IMAGING IN THE SACROILIAC JOINTS AND THE SPINE SUSPICIOUS OF AXIAL SPONDYLOARTHRITIS IN THE GENERAL POPULATION IS ASSOCIATED WITH DIFFERENT FACTORS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 57-57	2.4	2
256	Do magnetic resonance training in spondyloarthritis improve the performance of rheumatologists for the recognition of sequences and lesions? <b>2020</b> , 8-11		
255	Treating to Target in Clinical Practice: The Results of a Questionnaire Completed by Greek Rheumatologists. <i>Mediterranean Journal of Rheumatology</i> , <b>2020</b> , 31, 145-151	1.4	
254	AB1083 CURRENT PRACTICE AND OPINIONS ON IMAGING-GUIDED INTERVENTIONAL PROCEDURES IN RHEUMATIC AND MUSCULOSKELETAL DISEASES: INTERIM RESULTS OF A MULTINATIONAL MULTIDISCIPLINARY SURVEY TO INFORM EULAR POINTS TO CONSIDER. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1830.2-1831	2.4	1
253	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 176-185	2.4	46
252	Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged . <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 186-192	2.4	42
251	Do NSAIDs affect radiographic progression in axial SpA?. <i>Nature Reviews Rheumatology</i> , <b>2020</b> , 16, 9-10	8.1	0
250	Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate. <i>BMJ Open</i> , <b>2020</b> , 10, e039059	3	2
249	Recommendation for the Management of Spondyloarthritis Patients in Kuwait. <i>Open Access Rheumatology: Research and Reviews</i> , <b>2020</b> , 12, 147-165	2.4	

248	Recognition of spondyloarthritis lesions on magnetic resonance imaging: Results of an educational intervention. <i>International Journal of Rheumatic Diseases</i> , <b>2020</b> , 23, 1651-1655	2.3	1
247	Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial. <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	4
246	Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial. <i>BMC Musculoskeletal Disorders</i> , <b>2020</b> , 21, 767	2.8	6
245	Update of imaging in the diagnosis and management of axial spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2020</b> , 34, 101628	5.3	3
244	Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 177	5.7	6
243	Response to: 'Correspondence on 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Fallon. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	6
242	Response to: 'Comment on: 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Gossec ' by Wei. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	19
241	Functional MR imaging beyond structure and inflammation-radiographic axial spondyloarthritis is associated with proteoglycan depletion of the lumbar spine. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 219	5.7	2
240	Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	4
239	Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 759-774	4.4	3
238	EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 69-76	2.4	31
237	Structural progression in axial spondyloarthritis. <i>Joint Bone Spine</i> , <b>2020</b> , 87, 131-136	2.9	17
236	Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 35-41	4.1	2
235	Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 285-288	5.3	20
234	Imaging of diffuse idiopathic skeletal hyperostosis (DISH). <i>RMD Open</i> , <b>2020</b> , 6,	5.9	12
233	Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	6
232	Does psoriatic axial spondyloarthritis phenotype correlate with imaging morphotype?. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 329-332	2.2	2
231	Spinal mobility in the cervical and lumbar spine correlates with magnetic resonance imaging findings for inflammatory and structural changes in patients with active ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 467-471	2.2	1

230	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1550-1558	2.4	81
229	The need for comparative data in spondyloarthritis. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 32	5.7	3
228	What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1220-1225	2.4	12
227	Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 111	5.7	144
226	Tapering bDMARDs in axial SpA - what is the current evidence?. <i>Nature Reviews Rheumatology</i> , <b>2019</b> , 15, 322-324	8.1	2
225	Added Value of Anti-CD74 Autoantibodies in Axial SpondyloArthritis in a Population With Low HLA-B27 Prevalence. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 574	8.4	14
224	HLA-B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study. <i>International Journal of Rheumatic Diseases</i> , <b>2019</b> , 22, 708-714	2.3	8
223	Detection of Erosions in Sacroiliac Joints of Patients with Axial Spondyloarthritis Using the Magnetic Resonance Imaging Volumetric Interpolated Breath-hold Examination. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1445-1449	4.1	24
222	Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. <i>Rheumatology</i> , <b>2019</b> , 58, 388-400	3.9	40
221	Observation by Magnetic Resonance Imaging of Sacroiliac Joint Ankylosis in Young Spondyloarthritis Patients Receiving Biologic Therapy: Comment on the Article by Bray et al. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 2128-2129	9.5	
220	Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. <i>Rheumatology and Therapy</i> , <b>2019</b> , 6, 435-450	4.4	9
219	Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations. <i>RMD Open</i> , <b>2019</b> , 5, e001004	5.9	16
218	The impact of sex and disease classification on patient-reported outcome measures in axial spondyloarthritis: a descriptive prospective cross-sectional study. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 221	5.7	6
217	Treat to Target in Axial Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>2019</b> , 45, 519-535	2.4	6
216	Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities. <i>European Journal of Rheumatology</i> , <b>2019</b> , 6, 38-47	1.7	7
215	FRI0421 IXEKIZUMAB SIGNIFICANTLY REDUCED PAIN, INFLAMMATION, AND FATIGUE IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLARTHRTIS (R-AXSPA)/ANKYLOSING SPONDYLITIS (AS) <b>2019</b> ,		1
214	FRI0101 NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR ETANERCEPT [NO EVIDENCE FOR A RELEVANT NOCEBO EFFECT ]A RETROSPECTIVE ANALYSIS OF REAL-LIFE DATA <b>2019</b> ,		2
213	OP0235 SECUKINUMAB IMPROVES AXIAL MANIFESTATIONS IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NSAIDS: PRIMARY ANALYSIS OF THE MAXIMISE TRIAL <b>2019</b> ,		13

212	THU0361 DIAGNOSTIC PERFORMANCE OF MRI LESIONS IN THE SACROILIAC JOINTS ACCORDING TO UPDATED ASAS LESION DEFINITIONS: A CENTRAL READER ASSESSMENT OF MRI SCANS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS CLASSIFICATION COHORT <b>2019</b> ,		1
211	FRI0380 SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES <b>2019</b> ,		1
210	Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. <i>RMD Open</i> , <b>2019</b> , 5, e001005	5.9	40
209	Implementation and role of modern musculoskeletal imaging in rheumatological practice in member countries of EULAR. <i>RMD Open</i> , <b>2019</b> , 5, e000950	5.9	12
208	Bildgebung bei axialer Spondyloarthritis [Herausforderungen und Limitationen. <i>Aktuelle Rheumatologie</i> , <b>2019</b> , 44, 321-331	0.1	
207	Assessments und Outcome-Parameter bei axialer Spondyloarthritis. <i>Aktuelle Rheumatologie</i> , <b>2019</b> , 44, 332-338	0.1	
206	Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. <i>Rheumatology</i> , <b>2019</b> , 58, 859-868	3.9	72
205	The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 997-1004	5.3	11
204	Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 729-735	9.5	20
203	Reply to: Bone marrow oedema on sacroiliac/spine MRI: is it really a sign of objective inflammation warranting treatment?. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 122, 11-12	2.2	
202	Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 699-705	2.4	73
201	Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness-to-Pay Approach. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 608-616	4.7	1
200	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 3-17	2.4	320
199	Dual-phase hybrid F-Fluoride Positron emission tomography/MRI in ankylosing spondylitis: Investigating the link between MRI bone changes, regional hyperaemia and increased osteoblastic activity. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2018</b> , 62, 313-319	1.7	10
198	Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis. <i>Rheumatology</i> , <b>2018</b> , 57, 1541-1547	3.9	35
197	TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 63-69	2.4	143
196	The Role of Imaging in Diagnosing Axial Spondyloarthritis. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 106	4.9	11
195	SAT0268 Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis <b>2018</b> ,		8



194	SAT0270 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis <b>2018</b> ,		2
193	Is undifferentiated spondyloarthritis a discrete entity? A debate. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 29-32	13.6	7
192	Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 293-299	2.4	49
191	Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 371-377	2.4	27
190	Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. <i>RMD Open</i> , <b>2018</b> , 4, e000749	5.9	14
189	LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study <b>2018</b> ,		3
188	The Impact of Fibromyalgia in Spondyloarthritis: From Classification Criteria to Outcome Measures. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 290	4.9	10
187	Imaging in axial spondyloarthritis: Changing concepts and thresholds. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2018</b> , 32, 342-356	5.3	9
186	Disease Modification in Axial Spondyloarthritis. <i>Current Treatment Options in Rheumatology</i> , <b>2018</b> , 4, 344-354	1.3	
185	Learning from the youngsters: ixekizumab in active ankylosing spondylitis. <i>Lancet, The</i> , <b>2018</b> , 392, 2415-2416	4.6	3
184	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , <b>2018</b> , 392, 2378-2387	4.0	120
183	Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. <i>Rheumatology</i> , <b>2018</b> , 57, 1390-1399	3.9	28
182	Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 50-55	2.2	59
181	Imaging of axial spondyloarthritis. New aspects and differential diagnoses. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 114, 35-42	2.2	5
180	Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1070-1077	2.4	161
179	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 978-991	2.4	801
178	Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , <b>2017</b> , 3, e000396	5.9	67
177	Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , <b>2017</b> , 3, e000397	5.9	50

176	Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. <i>RMD Open</i> , <b>2017</b> , 3, e000430	5.9	19
175	Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis - the TryCort study. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 73	5.7	4
174	Ocular involvement in patients with spondyloarthritis. <i>Rheumatology</i> , <b>2017</b> , 56, 2060-2067	3.9	14
173	Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time. <i>Rheumatology</i> , <b>2017</b> , 56, 1162-1166	3.9	24
172	Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. <i>Rheumatology</i> , <b>2017</b> , 56, 95-102	3.9	33
171	Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next. <i>RMD Open</i> , <b>2017</b> , 3, e000472	5.9	53
170	Patienten mit axialer Spondyloarthritis haben nicht nur Rückenschmerzen. <i>Orthopädie &amp; Rheuma</i> , <b>2017</b> , 20, 25-31	0	1
169	OP0023 Four-year imaging outcomes in axial spondyloarthritis patients treated with certolizumab pegol, including patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis <b>2017</b> ,		2
168	THU0359 Secukinumab demonstrates consistent safety over long-term exposure (up to 3 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials <b>2017</b> ,		3
167	Clinical characteristics of importance to outcome in patients with axial spondyloarthritis: protocol for a prospective descriptive and exploratory cohort study. <i>BMJ Open</i> , <b>2017</b> , 7, e015536	3	4
166	ASAS definition for sacroiliitis on MRI in SpA: applicable to children?. <i>Pediatric Rheumatology</i> , <b>2017</b> , 15, 24	3.5	21
165	MR signal in the sacroiliac joint space in spondyloarthritis: a new sign. <i>European Radiology</i> , <b>2017</b> , 27, 2024-2030		22
164	Chronic but not inflammatory changes at the Achilles' tendon differentiate patients with peripheral spondyloarthritis from other diagnoses - Results from a prospective clinical trial. <i>RMD Open</i> , <b>2017</b> , 3, e000541	5.9	9
163	Entzündliche Wirbelsäulenerkrankungen: axiale Spondyloarthritis. <i>Journal für Mineralstoffwechsel &amp; Muskuloskelettale Erkrankungen</i> , <b>2017</b> , 24, 67-75	0.1	
162	Causes of pain in patients with axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 107, 102-107	2.2	6
161	Imaging in Axial Spondyloarthritis. <i>Israel Medical Association Journal</i> , <b>2017</b> , 19, 712-718	0.9	3
160	Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 408-12	2.4	53
159	Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1704-12	4.1	20

158	Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-Inhibitors for Up to 10 Years. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 2142-2148	4.1	29
157	Quantification of Bone Marrow Edema by Magnetic Resonance Imaging Only Marginally Reflects Clinical Neck Pain Evaluation in Rheumatoid Arthritis and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 2131-2135	4.1	3
156	SAT0376 Serum CRP Levels Demonstrate Predictive Value for Radiographic and MRI Outcomes in Patients with Active as Treated with The TNF-Inhibitor Golimumab. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 803.2-804	2.4	
155	FRI0396 Which Is The Most Reliable Imaging Method for Detection of Structural Changes in The Sacroiliac Joints of Patients with Ankylosing Spondylitis? A Cross-Sectional Study Comparing MRI, CT and Conventional Radiographs. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 578.2-578	2.4	
154	OP0086 Which Cells Correspond To The Typical Signals for Fatty and Inflammatory Lesions Seen in Magnetic Resonance Imaging in Ankylosing Spondylitis? A Prospective Study Using Biopsy Material Obtained during Spinal Surgery -. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 87.1-87	2.4	
153	Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: An expert consensus. <i>Journal of International Medical Research</i> , <b>2016</b> , 44, 216-30	1.4	9
152	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1958-1963	2.4	259
151	Secukinumab (AIN457) in the treatment of ankylosing spondylitis. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 711-22	5.4	18
150	Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 901-6	4.1	11
149	MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1486-93	2.4	61
148	Diagnostic Value of MRI of the Sacroiliac Joints in Juvenile Spondyloarthritis. <i>Journal of the Belgian Society of Radiology</i> , <b>2016</b> , 100, 95		3
147	PROMs for Spondyloarthritis <b>2016</b> , 121-147		
146	THU0414 Inter SPA: Sensitivity and Specificity of Autoantibodies against CD74 in Early Axial Spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 338.3-339	2.4	0
145	OP0001 Effect of Secukinumab, An Interleukin-17a Inhibitor, on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of The Phase 3 Study, Measure 1. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 52.1-52	2.4	3
144	Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 304	5.7	21
143	Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. <i>RMD Open</i> , <b>2016</b> , 2, e000272	5.9	4
142	Imaging Scoring Methods in Axial Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>2016</b> , 42, 663-678	2.4	12
141	Non-radiographic axial spondyloarthritis: a classification or a diagnosis?. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, S5-6	2.2	6

140	Clinical experience with the European Ankylosing Spondylitis Infiximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 184-90	2.2	2
139	Limited role of gadolinium to detect active sacroiliitis on MRI in juvenile spondyloarthritis. <i>Skeletal Radiology</i> , <b>2015</b> , 44, 1637-46	2.7	32
138	Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1418-26	4.1	23
137	The contribution of imaging in the diagnosis and treatment of axial spondyloarthritis. <i>European Journal of Clinical Investigation</i> , <b>2015</b> , 45, 81-6	4.6	8
136	EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1327-39	2.4	284
135	Diagnostic value of MRI features of sacroiliitis in juvenile spondyloarthritis. <i>Clinical Radiology</i> , <b>2015</b> , 70, 1428-38	2.9	24
134	OP0171 Achievement of Remission of Inflammation in the Spine and Sacroiliac Joints Measured by Magnetic Resonance Imaging (MRI) in Patients with Axial Spondyloarthritis, and Associations Between MRI and Clinical Remission, Over 96 Weeks of Treatment with Certolizumab Pegol. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1312-135	2.4	1
133	Hybrid 18F-labeled Fluoride Positron Emission Tomography/Magnetic Resonance (MR) Imaging of the Sacroiliac Joints and the Spine in Patients with Axial Spondyloarthritis: A Pilot Study Exploring the Link of MR Bone Pathologies and Increased Osteoblastic Activity. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1431-7	4.1	37
132	OP0168 Secukinumab Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: 52-Week Data from Measure 2, A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 132.3-133	2.4	1
131	Classification and diagnosis of axial spondyloarthritis--what is the clinically relevant difference?. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 31-8	4.1	29
130	OP0045 Clinically Active Non-Radiographic Axial Spondyloarthritis Patients who Initially have a Negative MRI and Normal CRP May Develop a Positive MRI or Elevated CRP at a Later Timepoint. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 83.2-83	2.4	
129	THU0210 Secukinumab Efficacy in Anti-Tnf-Naive Patients and Patients Previously Exposed to Anti-Tnf Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (Measure 2) in Active Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 272.1-272	2.4	1
128	Do patients with ankylosing spondylitis adapt to their disease? Evidence from a 'then-test' in patients treated with TNF inhibitors. <i>RMD Open</i> , <b>2015</b> , 1, e000164	5.9	1
127	THU0234 Long-Term Efficacy of Infiximab in Patients with Ankylosing Spondylitis [Real Life Data Confirm the Potential for Dose Reduction by Stretching Infusion Intervals. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 281.2-281	2.4	
126	OP0038 Patients with Fibromyalgia (FM) do not Fulfill Classification Criteria for Axial Spondyloarthritis (AXSPA) but Patients with Axspa May Fulfill Classification Criteria for FM. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 80.2-80	2.4	1
125	Longitudinal Analyses of Presenteeism and Its Role as a Predictor of Sick Leave in Patients With Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 1578-85	4.7	11
124	Diagnositic value of pelvic enthesitis on MRI of the sacroiliac joints in enthesitis related arthritis. <i>Pediatric Rheumatology</i> , <b>2015</b> , 13, 46	3.5	17
123	AB0450 Outpatients' Biologic Agent Therapy in Private Practices in Western Germany [A Survey and a Retrospective Study. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1046.1-1046	2.4	

122	THU0235 The Role of C-Reactive Protein as a Predictor of Treatment Response in Patients with Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 281.3-282	2.4	
121	OP0041 MRI Inflammation and Fat Deposition Both Contribute to Syndesmophyte Formation at the Same Site: A Multi-Level Analysis in Patients with Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 81.2-82	2.4	
120	FRI0241 Assessment of Spinal Mobility in Axial Spondyloarthritis [First Validation Steps of a New Electronic Quantification Tool. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 512.1-512	2.4	
119	FRI0608 Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 648.2-648	2.4	
118	Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. <i>Expert Review of Clinical Immunology</i> , <b>2015</b> , 11, 935-46	5.1	12
117	THU0223 Serum Biomarkers Associated with Changes in Asdas and MRI Following Treatment of Ankylosing Spondylitis with Golimumab. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 277.1-277	2.4	
116	Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?. <i>RMD Open</i> , <b>2015</b> , 1, e000053	5.9	64
115	Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2534-48	59.2	619
114	THU0233 Secukinumab Reduces Sacroiliac Joint and Spinal Inflammation in Patients with Ankylosing Spondylitis: MRI Data from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study (MEASURE 1). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 281.1-281	2.4	5
113	Emerging drugs for the treatment of axial and peripheral spondyloarthritis. <i>Expert Opinion on Emerging Drugs</i> , <b>2015</b> , 20, 1-14	3.7	29
112	Imaging in spondyloarthritis <b>2015</b> , 960-969		2
111	Periphere Spondyloarthritis <b>2015</b> , 1-6		
110	THU0199 Functional Status Remains Stable Despite Continuous Radiographic Spinal Progression Over Ten Years in Patients with Ankylosing Spondylitis Receiving Anti-TNF Therapy. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 267.1-267	2.4	
109	The involvement of the spine in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S31-5	2.2	30
108	Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 710-5	2.4	195
107	High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1079-82 <sup>4</sup>	2.4	54
106	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 6-16	2.4	308
105	Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis. <i>Expert Opinion on Investigational Drugs</i> , <b>2014</b> , 23, 647-59	5.9	15

104	SAT0374 Do Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Respond Similarly Well to Nsaids? A Prospective Study Including Magnetic Resonance Imaging. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 729.1-729	2.4	
103	SAT0376 Spinal Mobility in the Cervical and the Lumbar Spine Correlates with Magnetic Resonance Imaging Findings in Patients with Ankylosing Spondylitis [More Results from the GO-RAISE Trial. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 730.1-730	2.4	
102	OP0049 Conventional Magnetic Resonance Imaging (MR), Hybrid 18F-Fluoride Positron Emission Tomography MRI (18F-F- PET/MRI) and Computer Tomography of the Spine [A Detailed Description of Pathologic Signals in Patients with Active Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 79.1-79	2.4	2
101	AB0700 Do Patients with Ankylosing Spondylitis Adapt to Their Disease: Evidence from A [When Test]n Patients Treated with Tnf-Inhibitors. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1036.1-1036	2.4	
100	AB0655 Are Patients with as Willing to Pay for Treatment with Infliximab?. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1021.3-1021	2.4	
99	SAT0375 The Distribution of Inflammatory Lesions in the Anterior and Posterior Structures of the Spine in Patients with Active Ankylosing Spondylitis and the Effect of Tnf-Alpha -Blockade. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 729.2-729	2.4	
98	FRI0155 Persistent Fatty Lesions in the Vertebrae in Ankylosing Spondylitis FAVOR Subsequent New Syndesmophytes: Imaging Results of the GO-RAISE Study. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 438.2-438	2.4	
97	AB1023 VEGF and CRP Serum Levels Lack Predictive Value for Outcomes as Assessed by Conventional Radiographs and Magnetic Resonance Imaging in Patients with Active Ankylosing Spondylitis Treated with the TNF Inhibitor Golimumab. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1138.3-1139	2.4	
96	Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2014</b> , 15, 344	2.8	2
95	Assessment of spinal pain. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2014</b> , 28, 875-87	5.3	16
94	FRI0127 Eular Recommendations for the Use of Imaging in Spondyloarthritis in Clinical Practice. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 427.2-428	2.4	3
93	The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1107-13	2.4	87
92	THU0108 Different Performance of the Major Disease Activity Measures ASDAS and BASDAI in Patients with Axial Spondyloarthritis Treated with Non-Steroidal Anti-Inflammatory Agents (NSAIDS) [Results from A Prospective Study. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 214.3-215	2.4	
91	Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1819-25	2.4	111
90	Axiale Spondyloarthritis (einschlie[lich ankylosierender Spondylitis) <b>2014</b> , 1-16		
89	Optimisation of rheumatology assessments - the actual situation in axial spondyloarthritis including ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , <b>2014</b> , 32, S-96-104	2.2	9
88	Opinion: Perspectives on imaging in axial spondyloarthritis. <i>Nature Reviews Rheumatology</i> , <b>2013</b> , 9, 498-502		13
87	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2013</b> , 382, 1705-13	40	449

86	Outcome assessment in axial spondyloarthritis-imaging techniques, their relation to outcomes and their use in clinical trials. <i>Indian Journal of Rheumatology</i> , <b>2013</b> , 8, S38-S43	0.5	1
85	Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. <i>Arthritis Research and Therapy</i> , <b>2013</b> , 15, R67	5.7	40
84	Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1891-6	4.1	11
83	Das Konzept der nicht-röntgenologischen axialen Spondyloarthritis. <i>Aktuelle Rheumatologie</i> , <b>2013</b> , 38, 92-96	0.1	
82	Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1104-7	2.4	9
81	Response to 'Evidence in Support of the Validity of the TNF Brake Hypothesis' by Maksymowych. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, e32-3	2.4	2
80	SAT0283 Living with axial spondyloarthritis: Patients are using different coping strategies. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 567.3-568	2.4	
79	FRI0291 MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a TNF inhibitor. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 412.2-412	2.4	1
78	OP0172 Inflammation and fatty degeneration are of similar importance for new bone formation in patients with ankylosing spondylitis treated with infliximab or other anti-TNF agents over 5 years. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 113.1-113	2.4	
77	THU0262 Sclerostin does not predict radiographic progression in patients on anti-tnf therapy [New results from the european ankylosing spondylitis (AS) infliximab cohort (EASIC). <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 243.2-243	2.4	
76	THU0270 European ankylosing spondylitis (AS) infliximab cohort (EASIC) long-term extension: Efficacy and safety of infliximab over a time period of more than 7 years in patients with AS. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 246.1-246	2.4	
75	THU0278 The effect of anti-tumor necrosis factor therapy with golimumab on radiographic progression in definite ankylosing spondylitis: 4-year results. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 249.2-249	2.4	2
74	FRI0279 High prevalence of anti-CD 74 antibodies with specificity for the class II-associated invariant chain peptide (clip) in patients with axial spondyloarthritis but not in controls. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 408.2-408	2.4	1
73	Targeted therapies: TNF-blockers in the treatment of spondyloarthritis <b>2013</b> , 60-71		
72	Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, S43-6	2.2	6
71	Scoring with the Berlin MRI method for assessment of spinal inflammatory activity in patients with ankylosing spondylitis: a calibration exercise among rheumatologists. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 883-8	2.2	3
70	Imaging in axial spondyloarthritis: diagnostic problems and pitfalls. <i>Rheumatic Disease Clinics of North America</i> , <b>2012</b> , 38, 513-22	2.4	8
69	High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 572-4	2.4	162

68	Biologic therapies for spondyloarthritis: what is new?. <i>Current Rheumatology Reports</i> , <b>2012</b> , 14, 422-7	4.9	28
67	Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 1415-22	4.7	197
66	Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1278-88	2.4	162
65	A comparison of new bone formation in patients with ankylosing spondylitis and patients with diffuse idiopathic skeletal hyperostosis: a retrospective cohort study over six years. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 1127-33		48
64	First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. <i>Rheumatology</i> , <b>2012</b> , 51, 1388-96	3.9	98
63	Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?. <i>Current Opinion in Rheumatology</i> , <b>2012</b> , 24, 252-60	5.3	27
62	Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. <i>Rheumatology</i> , <b>2012</b> , 51, 1378-87	3.9	55
61	The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1207-11	2.4	58
60	MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 2002-5	2.4	61
59	MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 369-73	2.4	99
58	Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 878-84	2.4	64
57	2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 896-904	2.4	681
56	Spondyloarthritides. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2011</b> , 25, 825-42	5.3	33
55	The natural course of radiographic progression in ankylosing spondylitis: differences between genders and appearance of characteristic radiographic features. <i>Current Rheumatology Reports</i> , <b>2011</b> , 13, 383-7	4.9	32
54	Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. <i>Rheumatology</i> , <b>2011</b> , 50, 1690-9	3.9	84
53	Imaging of axial spondyloarthritis including ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70 Suppl 1, i97-103	2.4	51
52	OMERACT magnetic resonance imaging initiative on structural and inflammatory lesions in ankylosing spondylitis--report of a special interest group at OMERACT 10 on sacroiliac joint and spine lesions. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 2051-4	4.1	14
51	A stratified model for health outcomes in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1758-64	2.4	43



50	Anti-TNF-alpha therapy with infliximab in spondyloarthritides. <i>Expert Review of Clinical Immunology</i> , <b>2010</b> , 6, 9-19	5.1	11
49	Current controversies in spondyloarthritis: SPARTAN. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 2617-23	4.1	10
48	Microsurgical nerve root decompression in scoliotic lumbar spines-the relationship between important anatomical structures in correlation to imaging and implications for daily practice: anatomic cadaveric study. <i>Journal of Neurosurgery: Spine</i> , <b>2010</b> , 13, 123-32	2.8	2
47	Hip involvement in ankylosing spondylitis: what is the verdict?. <i>Rheumatology</i> , <b>2010</b> , 49, 3-4	3.9	67
46	Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 1520-7	2.4	538
45	Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 1334-9	2.4	39
44	The natural course of radiographic progression in ankylosing spondylitis--evidence for major individual variations in a large proportion of patients. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 997-1002	4.1	130
43	Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 764-71		67
42	The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 717-27		459
41	Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 3257-62		237
40	The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68 Suppl 2, ii1-44	2.4	800
39	Treatment of ankylosing spondylitis and other spondyloarthritides. <i>Current Opinion in Rheumatology</i> , <b>2009</b> , 21, 324-34	5.3	24
38	The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , <b>2008</b> , 10, R104	5.7	147
37	Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 3063-70		399
36	Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. <i>Annals of the Rheumatic Diseases</i> , <b>2008</b> , 67, 340-5	2.4	87
35	Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 639-47		139
34	Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 910-5	2.4	180
33	Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. <i>Rheumatology</i> , <b>2007</b> , 46, 1450-3	3.9	142

32	Magnetic resonance imaging in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , <b>2007</b> , 19, 346-53.	3.3	36
31	Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 510-5	4.1	35
30	Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 862-70	4.1	80
29	Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis?. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 871-3	4.1	26
28	Magnetic resonance imaging in spondyloarthropathies. <i>Joint Bone Spine</i> , <b>2006</b> , 73, 1-3	2.9	37
27	Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , <b>2006</b> , 65, 1147-53	2.4	119
26	Magnetic resonance imaging in ankylosing spondylitis. <i>Future Rheumatology</i> , <b>2006</b> , 1, 423-431		4
25	L'imagerie par résonance magnétique dans les spondylarthropathies. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2006</b> , 73, 1-3	0.1	1
24	The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms. <i>Clinical Rheumatology</i> , <b>2006</b> , 25, 648-58	3.9	12
23	Infection and work stress are potential triggers of ankylosing spondylitis. <i>Clinical Rheumatology</i> , <b>2006</b> , 25, 660-6	3.9	17
22	Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey. <i>Clinical Rheumatology</i> , <b>2006</b> , 25, 794-800	3.9	41
21	Therapy of ankylosing spondylitis--a review. Part I: Conventional medical treatment and surgical therapy. <i>Scandinavian Journal of Rheumatology</i> , <b>2005</b> , 34, 97-108	1.9	30
20	Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. <i>Scandinavian Journal of Rheumatology</i> , <b>2005</b> , 34, 178-90	1.9	43
19	Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. <i>Arthritis Research</i> , <b>2005</b> , 7, R439-44		167
18	Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. <i>Arthritis Research</i> , <b>2005</b> , 7, P30		2
17	Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis. <i>Arthritis Research</i> , <b>2005</b> , 7, P28		78
16	Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. <i>Arthritis Research</i> , <b>2005</b> , 7, P27		1
15	Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab. <i>Arthritis Research</i> , <b>2005</b> , 7, P31		78

14	Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 1216-23		164
13	Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 2447-51		301
12	Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 53, 856-63		121
11	Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. <i>Rheumatology</i> , <b>2005</b> , 44, 1525-30	3.9	117
10	Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 730-4	2.4	122
9	Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 1305-10	2.4	104
8	Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 1141-4	2.4	103
7	Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. <i>Rheumatology</i> , <b>2005</b> , 44, 670-6	3.9	158
6	Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 1462-6	2.4	146
5	Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 2050-5	4.1	58
4	Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. <i>Annals of the Rheumatic Diseases</i> , <b>2004</b> , 63, 1046-55	2.4	122
3	Current concepts in the therapy of the spondyloarthritides. <i>BioDrugs</i> , <b>2004</b> , 18, 307-14	7.9	5
2	Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 48, 1126-36		301
1	Early Recognition and Treatment of Spondyloarthritis: A Timeless Challenge. <i>European Medical Journal Rheumatology</i> , 72-79		1